526 related articles for article (PubMed ID: 22868389)
1. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism.
Liu L; Liu J; Wong WT; Tian XY; Lau CW; Wang YX; Xu G; Pu Y; Zhu Z; Xu A; Lam KS; Chen ZY; Ng CF; Yao X; Huang Y
Hypertension; 2012 Sep; 60(3):833-41. PubMed ID: 22868389
[TBL] [Abstract][Full Text] [Related]
2. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress.
Liu L; Liu J; Tian XY; Wong WT; Lau CW; Xu A; Xu G; Ng CF; Yao X; Gao Y; Huang Y
Antioxid Redox Signal; 2014 Oct; 21(11):1571-81. PubMed ID: 24328731
[TBL] [Abstract][Full Text] [Related]
3. Novel biological action of the dipeptidylpeptidase-IV inhibitor, sitagliptin, as a glucagon-like peptide-1 secretagogue.
Sangle GV; Lauffer LM; Grieco A; Trivedi S; Iakoubov R; Brubaker PL
Endocrinology; 2012 Feb; 153(2):564-73. PubMed ID: 22186413
[TBL] [Abstract][Full Text] [Related]
4. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.
Jackson EK; Mi Z; Tofovic SP; Gillespie DG
Hypertension; 2015 Jan; 65(1):238-49. PubMed ID: 25368027
[TBL] [Abstract][Full Text] [Related]
5. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor.
Abd El Motteleb DM; Elshazly SM
Eur J Pharmacol; 2013 Nov; 720(1-3):158-65. PubMed ID: 24238127
[TBL] [Abstract][Full Text] [Related]
6. Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A.
Oeseburg H; de Boer RA; Buikema H; van der Harst P; van Gilst WH; Silljé HH
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1407-14. PubMed ID: 20448207
[TBL] [Abstract][Full Text] [Related]
7. Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats.
Giannocco G; Oliveira KC; Crajoinas RO; Venturini G; Salles TA; Fonseca-Alaniz MH; Maciel RM; Girardi AC
Eur J Pharmacol; 2013 Jan; 698(1-3):74-86. PubMed ID: 23051671
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
9. Protein kinase Cβ mediates downregulated expression of glucagon-like peptide-1 receptor in hypertensive rat renal arteries.
Liu L; Liu J; Gao Y; Ng CF; Yu X; Dou D; Huang Y
J Hypertens; 2015 Apr; 33(4):784-90; discussion 790. PubMed ID: 25915883
[TBL] [Abstract][Full Text] [Related]
10. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase.
Tang ST; Su H; Zhang Q; Tang HQ; Wang CJ; Zhou Q; Wei W; Zhu HQ; Wang Y
Int J Mol Med; 2016 Jun; 37(6):1558-66. PubMed ID: 27122056
[TBL] [Abstract][Full Text] [Related]
11. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Matsubara J; Sugiyama S; Sugamura K; Nakamura T; Fujiwara Y; Akiyama E; Kurokawa H; Nozaki T; Ohba K; Konishi M; Maeda H; Izumiya Y; Kaikita K; Sumida H; Jinnouchi H; Matsui K; Kim-Mitsuyama S; Takeya M; Ogawa H
J Am Coll Cardiol; 2012 Jan; 59(3):265-76. PubMed ID: 22240132
[TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner.
Hausenloy DJ; Whittington HJ; Wynne AM; Begum SS; Theodorou L; Riksen N; Mocanu MM; Yellon DM
Cardiovasc Diabetol; 2013 Oct; 12():154. PubMed ID: 24148218
[TBL] [Abstract][Full Text] [Related]
13. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
[TBL] [Abstract][Full Text] [Related]
14. Attenuated diuresis and natriuresis in response to glucagon-like peptide-1 in hypertensive rats are associated with lower expression of the glucagon-like peptide-1 receptor in the renal vasculature.
Savignano FA; Crajoinas RO; Pacheco BPM; Campos LCG; Shimizu MHM; Seguro AC; Girardi ACC
Eur J Pharmacol; 2017 Sep; 811():38-47. PubMed ID: 28576404
[TBL] [Abstract][Full Text] [Related]
15. The dipeptidyl peptidase-4 inhibitor-sitagliptin modulates calcium dysregulation, inflammation, and PPARs in hypertensive cardiomyocytes.
Lee TI; Kao YH; Chen YC; Huang JH; Hsu MI; Chen YJ
Int J Cardiol; 2013 Oct; 168(6):5390-5. PubMed ID: 24012160
[TBL] [Abstract][Full Text] [Related]
16. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
17. Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.
Waget A; Cabou C; Masseboeuf M; Cattan P; Armanet M; Karaca M; Castel J; Garret C; Payros G; Maida A; Sulpice T; Holst JJ; Drucker DJ; Magnan C; Burcelin R
Endocrinology; 2011 Aug; 152(8):3018-29. PubMed ID: 21673098
[TBL] [Abstract][Full Text] [Related]
18. The DPP-4 inhibitor linagliptin and the GLP-1 receptor agonist exendin-4 improve endothelium-dependent relaxation of rat mesenteric arteries in the presence of high glucose.
Salheen SM; Panchapakesan U; Pollock CA; Woodman OL
Pharmacol Res; 2015 Apr; 94():26-33. PubMed ID: 25697548
[TBL] [Abstract][Full Text] [Related]
19. Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension.
Liu L; Liu J; Huang Y
J Cardiovasc Pharmacol; 2015 May; 65(5):399-405. PubMed ID: 25384196
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway.
Samikannu B; Chen C; Lingwal N; Padmasekar M; Engel FB; Linn T
PLoS One; 2013; 8(12):e82639. PubMed ID: 24349326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
